BXN — Bioxyne Income Statement
0.000.00%
Last trade - 00:00
- AU$19.02m
- AU$17.27m
- AU$5.16m
2019 June 30th | 2020 June 30th | 2021 June 30th | R2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.13 | 2.26 | 2.11 | 0.464 | 5.16 |
Cost of Revenue | |||||
Gross Profit | 1.14 | 1.22 | 1.08 | 0.135 | 1.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.61 | 2.99 | 2.68 | 0.962 | 7.31 |
Operating Profit | -1.47 | -0.727 | -0.572 | -0.499 | -2.15 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.27 | -0.593 | -0.496 | -0.494 | -1.96 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.27 | -0.593 | -0.496 | -0.494 | -1.96 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1.27 | -0.593 | -0.496 | -0.494 | -1.94 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.27 | -0.593 | -0.496 | -0.494 | -1.94 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.002 | -0.001 | -0 | -0.001 | -0.001 |